[Skip to Content]
[Skip to Content Landing]
May 16, 1990


JAMA. 1990;263(19):2660-2661. doi:10.1001/jama.1990.03440190116061

A major theme in neurology for the last several years has been clinical trials of therapy for disorders that were thought to be untreatable. The course of Parkinson's disease, for example, has been greatly modified by the introduction of therapies that increase activity in the dopaminergic system. During this last year, another approach to this disease has been undertaken through attempts to delay and slow its manifestations. The variable course and heterogeneous manifestations of Parkinson's disease make clinical trials difficult. However, a multicenter controlled clinical trial with many safeguards was devised.1 The clinical trial is still in progress, but the interim results show that 10 mg/d of selegiline (Deprenyl), a monoamine oxidase inhibitor, slowed the end point, which was a decision to treat the patient with levodopa therapy. The treatment also had a significant effect in slowing the time until it was necessary for the patient to give up